Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
A phase 1/2 trial of FPI-2265, Actinium-225 PSMA agents, Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.
Overview
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07590934 by AstraZeneca, with 152 participants planned, started 2026-06-03 and due to reach its primary completion in 2029-09-25. Interventions recorded: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent). Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shares FPI-2265, AstraZeneca, Actinium-225, Prostate cancer.
- TrialTargeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares FPI-2265, AstraZeneca, Actinium-225, Prostate cancer.
- AgentActinium-225 FPI-2068
Shares FPI-2265, AstraZeneca, Actinium-225.
- TrialCHAARTED (E3805)
Shares Docetaxel, Prostate cancer.
- TrialAlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
Shares AstraZeneca, Actinium-225 PSMA agents, Actinium-225, Prostate cancer.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Actinium-225, Prostate cancer.
- IdeaAlpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer
Shares Actinium-225 PSMA agents, Actinium-225.